198 related articles for article (PubMed ID: 12624792)
1. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
3. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration.
Pei JJ; Braak H; Gong CX; Grundke-Iqbal I; Iqbal K; Winblad B; Cowburn RF
Acta Neuropathol; 2002 Oct; 104(4):369-76. PubMed ID: 12200623
[TBL] [Abstract][Full Text] [Related]
5. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
6. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains.
Pearson AG; Byrne UT; MacGibbon GA; Faull RL; Dragunow M
Neurosci Lett; 2006 May; 398(3):246-50. PubMed ID: 16481106
[TBL] [Abstract][Full Text] [Related]
7. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
8. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Pei JJ; Sjögren M; Winblad B
Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
[TBL] [Abstract][Full Text] [Related]
10. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
11. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.
Sugata H; Matsuo K; Nakagawa T; Takahashi M; Mukai H; Ono Y; Maeda K; Akiyama H; Kawamata T
Neurosci Lett; 2009 Aug; 459(2):96-9. PubMed ID: 19414059
[TBL] [Abstract][Full Text] [Related]
12. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
13. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
Griffin RJ; Moloney A; Kelliher M; Johnston JA; Ravid R; Dockery P; O'Connor R; O'Neill C
J Neurochem; 2005 Apr; 93(1):105-17. PubMed ID: 15773910
[TBL] [Abstract][Full Text] [Related]
14. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions.
Togo T; Akiyama H; Iseki E; Uchikado H; Kondo H; Ikeda K; Tsuchiya K; de Silva R; Lees A; Kosaka K
Acta Neuropathol; 2004 Jun; 107(6):504-8. PubMed ID: 15024583
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease.
Maeda S; Sahara N; Saito Y; Murayama S; Ikai A; Takashima A
Neurosci Res; 2006 Mar; 54(3):197-201. PubMed ID: 16406150
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology.
Maurage CA; Sergeant N; Ruchoux MM; Hauw JJ; Delacourte A
Acta Neuropathol; 2003 Feb; 105(2):89-97. PubMed ID: 12536218
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease.
Umahara T; Uchihara T; Tsuchiya K; Nakamura A; Iwamoto T; Ikeda K; Takasaki M
Acta Neuropathol; 2004 Oct; 108(4):279-86. PubMed ID: 15235803
[TBL] [Abstract][Full Text] [Related]
20. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
